Diagnostic company LipoScience announced a new agreement to place the Vantera Clinical Analyzer within Scripps Health facilities, marking the first placement of the device in the state of California. The agreement makes NMR lipoprotein testing on the analyzer available to Scripps Health customers.
The Vantera Clinical Analyzer is able to identify and quantify concentrations of lipoproteins using NMR spectroscopy and proprietary signal processing algorithms. This analysis provides the concentration of low-density lipoprotein particles (LDL-P) and other lipoprotein information from a simple blood test. An integral component of the company’s NMR LipoProfile test, LDL-P is the first FDA-cleared assay on the Vantera Clinical Analyzer.
Adopting and decentralizing the Vantera Clinical Analyzer into clinical labs will ultimately provide broad access to the NMR LipoProfile test, also reducing sample processing turnaround time and providing value to physicians who are focused on delivering quality patient care and personalized cardiovascular disease (CVD) management. More than 10 million NMR LipoProfile tests have been ordered to date.
“LDL particle number is increasingly understood to be a more clinically reliable measure of LDL, and we believe it should be a key component of cardiovascular disease management,” said Michael Quigley, M.D., medical director of Scripps Medical Laboratory. “By placing the Vantera Clinical Analyzer within our facilities, Scripps Health will be able to help physicians devise personalized cardiovascular risk-reduction strategies tailored to individual patients’ needs.”
For more information, visit www.liposcience.com or www.theparticletest.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment